Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Conference March 7, 2024 4:30 PM ET

Company Participants

Lisa Miller - Vice President, IR

Rick Hawkins - CEO and Chairman

John McKew - President and CSO

Duke Pitukcheewanont - CMO

Lori Lawley - CFO

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Leland Gershell - Oppenheimer

Ed White - H.C. Wainwright

Catherine Novack - Jones Trading

Operator

Good afternoon and welcome to Lumos Pharma’s 2023 Fourth Quarter and Year End Conference Call. Currently all participants are on a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I will now turn the call over to Lisa Miller, Vice President of Investor Relations. Please go ahead.

Lisa Miller

Thank you, operator. Before we proceed with this call, I'd like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release we issued this afternoon and in our forum 10-K which may be accessed from the investors page of the company's website.

Speaking on today's call will be Rick Hawkins, CEO and Chairman; John McKew, our President and Chief Scientific Officer; Dr. Duke Pitukcheewanont, Chief Medical Officer; and Lori Lawley, our Chief Financial Officer. Following our prepared remarks, the management team will be available for a question-and-answer session.

I will now turn the call over to Rick.

Rick Hawkins

Thank you, Lisa, and good afternoon, everyone. After the market closed today, we issued a press release announcing our results for 2023. I'm pleased to report that 2023 was a successful year for Lumos, led by our announcement of positive top-line results from our OraGrowtH210 and OraGrowtH212 trials of LUM-201 in pediatric growth hormone deficiency.

On today's call, we'll briefly summarize our trial results and other progress made in 2023, recap highlights for recent weeks and layout plans for 2024. Then we'll be happy to answer your questions.